Abstract
whereas for men with PSA 2 ng/mL, reduction in cancer-mortality was large with a number needed to screen (NNS) and diagnose (NND) to avoid one prostate cancer death by 15 years being 16 and 3, respectively. CONCLUSIONS: The ratio of benefits to harms of PSA screening varies dramatically with levels of PSA in blood at age 60. Previous estimates of the effect of PSA-screening have been an average of very different subgroups with low and high risk. Our data suggest that men with a PSA 2 at age 60 seems very beneficial, with the number needed to screen and treat being extremely favorable.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
